# Adversarial verification verdict — pleuropulmonary_blastoma.md

1. DOSE LEAK: none. Grepped for numeric mg / mg-m2 / mg/kg / AUC / Gy / cGy / q-week / day-N / cycle-N
   patterns across the whole sidecar — zero matches. The chemo-backbone paragraph explicitly names
   drug classes only (alkylating agent, anthracycline-based component, vinca alkaloid/actinomycin-based
   component) and states "Doses and schedules are not detailed here and belong in a separate structured
   protocol reference."

2. UNGROUNDED CLAIMS: none beyond what the draft agent already disclosed and hedged. Verified directly
   against devita.txt:
   - Line 67647 ("4.4 Pleuropulmonary blastoma") is confirmed to be a bare WHO thoracic-tumour
     classification table entry (list of mesenchymal lung tumor subtypes) with no surrounding management
     narrative.
   - Line 67933's "TP53, DICER1, and CTNNB1" hit is confirmed to belong to "pulmonary blastoma" — an
     adult, sarcomatoid/biphasic NSCLC-associated entity described a few paragraphs earlier as
     "large, well-delimited, biphasic, high-grade invasive lung tumors ... fetal adenocarcinoma and
     primitive mesenchymal stroma" — not pediatric PPB. The sidecar correctly does NOT cite this as
     support for pediatric PPB DICER1 biology.
   - No other DeVita hits exist for "pleuropulmonary," DICER1+PPB, "cambium," or pediatric lung tumor
     chapters that could have been mined instead.
   - Every clinical claim in the sidecar (Type I/Ir/II/III staging-by-type, cambium layer risk in Type I,
     surgery-first approach, sarcoma-type chemo backbone by drug class only, radiotherapy's selective
     role, DICER1 germline testing + associated tumor spectrum — cystic nephroma, Sertoli-Leydig cell
     tumor, multinodular goiter/thyroid carcinoma, ciliary body medulloepithelioma, nasal
     chondromesenchymal hamartoma, brain/bone surveillance for solid-type disease) is inline-tagged
     "general oncology standard, not from DeVita's section on this disease" — none is presented as
     DeVita-sourced. These are standard, uncontroversial pediatric-oncology/DICER1-syndrome facts
     (consistent with COG/International PPB Registry literature) rather than fabricated specifics; no
     named regimen, trial, or outcome statistic is asserted anywhere in the file.
   - No NCCN citation is claimed; the sources line explicitly states NCCN was not consulted this pass.

3. CITATION: present — "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
   Oncology, 12th ed. (section located did not contain substantive management content specific to this
   disease); NCCN Guidelines not consulted in this pass." Name-only, no page numbers, and honestly
   qualifies the citation rather than overclaiming grounding.

4. VERDICT: CLEAN (ready for R1).
   Note for R1: this file is a documented DeVita-grounding gap, not a quality defect — DeVita's 12th ed.
   genuinely has no substantive PPB management content (verified independently above), and the draft
   agent disclosed this transparently instead of fabricating DeVita support. R1 should treat this as a
   flagged-for-manual-sourcing item (pediatric oncology text / COG-PPB registry protocol) rather than a
   rejection.
